RecruitingNCT06527521
Prevalence of Amyloidosis in Trauma Patients
Prevalence of Amyloidosis in Trauma Patients Using Red Flags Tool
Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Enrollment
246 participants
Start Date
Nov 13, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.
Eligibility
Inclusion Criteria3
- Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness > 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP > 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause.
- Ability to cooperate in the necessary evaluations.
- Signed informed consent for inclusion in the study, either by the participant or their legal representative.
Exclusion Criteria1
- \- Participants previously diagnosed with amyloidosis cannot be included in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDURETraumatologic surgery
Patients undergoing trauma surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06527521
Related Trials
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT051458163 locations
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT0667223714 locations
NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis
NCT062517781 location
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
NCT069748771 location
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT057584931 location